Study Enrollment

Your details will not be published or shared.

Clinical Trial

Evaluating Patient-Reported Outcomes Monitoring in Routine Care of Patients with Chronic Myeloid Leukemia for Increasing Adherence and Clinical Response to Therapy: The EMPATHY Pilot Study

This study seeks to develop an online platform for systematic monitoring of patient-reported adverse effects (AE) assessment that is tailored to the unique demands of tyrosine kinase inhibitors (TKI) therapy (oral medication) for chronic myeloid leukemia (CML). This study also seeks to assess patient and physician acceptability and satisfaction with use of this platform in CML routine practice and evaluate its value in improving symptom management, health related quality of life (HRQoL), adherence to therapy as well as preliminary efficacy.

Eligibility Criteria

  • Patient inclusion criteria will include: 1) Diagnosis of Philadelphia chromosome positive and/or BCR-ABL positive chronic myeloid leukemia (CML) 2) Adult patients (?18 years) 3) Written informed consent from patient?s physician as a participant. Physician inclusion criteria will include: 1) Provider of clinical care for patient who meets inclusion criteria for the study Please note that physician consent is required for the patient to be enrolled as a participant in the study.

Contact Information

    Mohammad Mian

    (706) 721-0110